| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 10/02/2002 | EP1244683A1 21 human secreted proteins |
| 10/02/2002 | EP1244651A1 Diamidine compounds as dna minor groove binders |
| 10/02/2002 | EP1244630A1 Amphiphilic polyamines, the use and method for synthesis thereof |
| 10/02/2002 | EP1244466A2 Activation and inhibition of the immune system |
| 10/02/2002 | EP1244457A2 Methods and compositions related to modulators of annexin and cartilage homeostasis |
| 10/02/2002 | EP1244433A2 Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule |
| 10/02/2002 | EP1244350A2 Prostatic cell line and use thereof to obtain an established prostatic cancer in an animal |
| 10/02/2002 | EP1077068B9 Utilization of interferon alpha 5 in the treatment of viral hepatopathies |
| 10/02/2002 | EP0717750B1 Double-stranded peptide nucleic acids |
| 10/02/2002 | EP0691988B1 Inhibitor of stem cell proliferation and uses thereof |
| 10/02/2002 | EP0668933B1 Use of methioninase as an antitumor agent in anti-methionine chemotherapy |
| 10/02/2002 | EP0600930B1 Diagnosis and treatment of autoimmune diseases |
| 10/02/2002 | DE10112825A1 HESylierung von Wirkstoffen in wässriger Lösung HESylation of drugs in aqueous solution |
| 10/02/2002 | CN1372598A Methods of inducing cell death |
| 10/02/2002 | CN1372594A OX2 receptor homologs |
| 10/02/2002 | CN1372569A Keratinocyte growth factor-2 |
| 10/02/2002 | CN1372568A Vaccin |
| 10/02/2002 | CN1372450A Enhanced wound converage to enhance wound healing |
| 10/01/2002 | WO2001076630A1 Diagnostics and remedies for rheumatoid arthritis |
| 10/01/2002 | US6458838 4-phenylbutyrate treatment of cells from both x-ald patients and x-ald knockout mice results in decreased levels of and increased .beta.-oxidation of very-long-chain fatty acids; increased expression of the peroxisomal protein aldrp; and |
| 10/01/2002 | US6458588 Renal stem cells and uses thereof |
| 10/01/2002 | US6458586 Replication of defective vectors with mutations and deletions; gene therapy, vaccines, genetic engineering |
| 10/01/2002 | US6458578 Recombinant cell line produces adenoviral gene products E1 and DEF-A, and/or DEF-B |
| 10/01/2002 | US6458574 Highly purified alpha-galactose a glycoforms by charge alterations by increasing the sialic acid content and/or by increasing the phosphorylation; half-life; bioavailability; fabry's disease; cardiovascular disorders |
| 10/01/2002 | US6458567 Hepatitis C Virus ribozymes |
| 10/01/2002 | US6458564 Amino acid sequence of the protease; for treating imbalance of desquamation |
| 10/01/2002 | US6458561 Human NIM1 kinase |
| 10/01/2002 | US6458560 Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| 10/01/2002 | US6458529 Assays for promoter operability in central nervous system cells |
| 10/01/2002 | US6458026 Transfection complex comprising a first component comprising one or more lipids, a second component comprising an oligolysine linked via a peptide bond to an integrin-binding peptide, and a third component comprising a nucleic acid |
| 10/01/2002 | CA2404919A1 Diagnostic and therapeutic agents for rheumatoid arthritis |
| 10/01/2002 | CA2248047C Antagonism of endothelin actions |
| 09/28/2002 | CA2340455A1 Nucleic acids and proteins of the mycoplasma hyopneumoniae mhp3 gene and uses thereof |
| 09/26/2002 | WO2002075304A1 Method of examining allergic disease |
| 09/26/2002 | WO2002074996A1 Gene regulation |
| 09/26/2002 | WO2002074981A2 Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
| 09/26/2002 | WO2002074980A2 Muteins of hypoxia inducible factor alpha and methods of use thereof |
| 09/26/2002 | WO2002074911A2 Identification of gene expression alterations underlying the aging process in mammals |
| 09/26/2002 | WO2002074908A2 Methods and reagents for regulating apoptosis |
| 09/26/2002 | WO2002074907A2 Methods of modulating surfactant production |
| 09/26/2002 | WO2002074808A2 Modified insulin with reduced immunogenicity |
| 09/26/2002 | WO2002074807A2 Chimpanzee erythropoietin (chepo) - immunoadhesins |
| 09/26/2002 | WO2002074805A1 Soluble rage protein |
| 09/26/2002 | WO2002074794A2 Compositions useful in gene therapy |
| 09/26/2002 | WO2002074338A1 Semi-allogenic anti-tumour vaccine with hla haplo-identical antigen-presenting cells |
| 09/26/2002 | WO2002074323A2 Using neural thread proteins to treat tumors and other hyperproliferative disorders |
| 09/26/2002 | WO2002074249A2 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 09/26/2002 | WO2002074239A2 Compositions and methods for the treatment and clinical remission of psoriasis |
| 09/26/2002 | WO2002074234A2 Method and composition for treatment of skeletal dysplasias |
| 09/26/2002 | WO2002074158A2 Two-phase processing of thermosensitive polymers for use as biomaterials |
| 09/26/2002 | WO2002062999A8 Proteins and nucleic acids encoding same |
| 09/26/2002 | WO2002053581A3 Spliceosome mediated rna trans-splicing |
| 09/26/2002 | WO2002046214A3 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 09/26/2002 | WO2002038752A3 Use of a helminth for the in vivo delivery of a medicament |
| 09/26/2002 | WO2002038609A3 Apolipoprotein conjugates |
| 09/26/2002 | WO2002036167A8 Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids |
| 09/26/2002 | WO2002015918A3 Method and compositions for promoting osteogenesis |
| 09/26/2002 | WO2001090159B1 Compositions and methods for delivery of a molecule into a cell |
| 09/26/2002 | WO2001073002A3 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 09/26/2002 | WO2001070969A3 Regulation of human latrophilin-like g protein-coupled receptor |
| 09/26/2002 | WO2001047953A3 Antibodies against plasma cells |
| 09/26/2002 | WO2001023421A9 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 09/26/2002 | WO2001019977A9 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 09/26/2002 | WO2001019393A9 Delivering to eucaryotic cells bacterial proteins that are secreted via type iii secretion systems |
| 09/26/2002 | WO2000027868A9 Connective tissue growth factor (ctgf) and methods of use |
| 09/26/2002 | US20020138865 In vitro transfection, storage and transfer of male germ cells for generation of transgenic species & genetic therapies |
| 09/26/2002 | US20020137889 Stress resistant retroviruses |
| 09/26/2002 | US20020137792 Use of an LTB4 antagonist for the treatment or prevention of diseases caused by increased expression of mucin genes |
| 09/26/2002 | US20020137755 Tyrosine kinase inhibitors |
| 09/26/2002 | US20020137719 Particulate compositions for chemical synthesis |
| 09/26/2002 | US20020137718 Nucleozymes |
| 09/26/2002 | US20020137717 Use of chimeric mutational vectors to change endogenous nucleotide sequences in solid tissues |
| 09/26/2002 | US20020137716 Administering nucleotide sequence |
| 09/26/2002 | US20020137711 Suppression of hematopoietic enzyme; organ grafting |
| 09/26/2002 | US20020137707 Insertion of polynucleotide into blood vessel |
| 09/26/2002 | US20020137705 Osteoporosis |
| 09/26/2002 | US20020137703 Genetic engineering; insertion vector into polypeptides |
| 09/26/2002 | US20020137702 Yeast receptor |
| 09/26/2002 | US20020137701 Administering exogenous genes |
| 09/26/2002 | US20020137700 Nucleic acids; genetic engineering |
| 09/26/2002 | US20020137679 Thrombospondins-1 and -2 are adhesive glycoproteins proteins that are angiogenesis inhibitors; portions of TSP- 1, TSP-2, endostatin, angiostatin, platelet factor 4, or prolactin linked to a portion of cartilage oligoeric matrix protein |
| 09/26/2002 | US20020137675 Polypeptides, termed PROTX polypeptides, as well as polynucleotides encoding PROTX and antibodies that immuno-specifically bind to a PROTX, variant, mutant, or fragment of a PROTX; detection/treatment of pathological states; kits |
| 09/26/2002 | US20020137670 Transferrin polycation/DNA complexes for the systemic treatment of tumor diseases with cytotoxic proteins |
| 09/26/2002 | US20020137669 Treatment of dyskinesia |
| 09/26/2002 | US20020137213 Adenovirus particles with mutagenized fiber proteins |
| 09/26/2002 | US20020137210 Method for modifying genetic characteristics of an organism |
| 09/26/2002 | US20020137188 Method of modulating cell survival and reagents useful for same |
| 09/26/2002 | US20020137186 Lymphotropic agents and vectors |
| 09/26/2002 | US20020137182 For obtaining and using a polypeptide other than oncogene BCL-2 that affects programmed vertebrate cell death |
| 09/26/2002 | US20020137175 Human glycosylation enzymes |
| 09/26/2002 | US20020137143 Antigrowth regulator; cell differentiation; anticarcinogenic agents |
| 09/26/2002 | US20020137138 Modulating serotonin activity |
| 09/26/2002 | US20020137137 Genetic engineering; polypeptides |
| 09/26/2002 | US20020137135 Novel NPG-1 gene that is differentially expressed in prostate tumors |
| 09/26/2002 | US20020137129 Polypeptides; genetic engineering; drug development |
| 09/26/2002 | US20020137127 Culture product; polypeptides |
| 09/26/2002 | US20020137095 Reelin protein CR-50 epitope region |
| 09/26/2002 | US20020137049 Pablo, a polypeptide that interacts with Bcl-xL, and uses related thereto |
| 09/26/2002 | US20020137044 Novel nucleic acids and polypeptides |
| 09/26/2002 | US20020137028 Use of neuronal apoptosis inhibitor protein (naip) |